HUP0303801A2 - Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0303801A2 HUP0303801A2 HU0303801A HUP0303801A HUP0303801A2 HU P0303801 A2 HUP0303801 A2 HU P0303801A2 HU 0303801 A HU0303801 A HU 0303801A HU P0303801 A HUP0303801 A HU P0303801A HU P0303801 A2 HUP0303801 A2 HU P0303801A2
- Authority
- HU
- Hungary
- Prior art keywords
- optionally substituted
- alkyl
- aryl
- hydrogen atom
- independently
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 5
- -1 cycloheteroalkyl Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101000585507 Solanum tuberosum Cytochrome b-c1 complex subunit 7 Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány tárgya (I) általános képletű vegyület - ahol W jelentéseSO2, CO, CONH, CSNH vagy (CH2)x; X jelentése O, SOy vagy NR13; Yjelentése CR14 vagy N; Z jelentése CR15 vagy N, azzal a megkötéssel,hogy ha Y jelentése N, akkor Z szükségszerűen CR15; m és x egymástólfüggetlenül 0 vagy 1 , 2 vagy 3; n és p egymástól függetlenül 1, 2vagy 3; R1 jelentése halogénatom, CN, OR16, CO2R17, CONR18R19,CNR2ONR21R22, SO2NR23R24, SOWR25 vagy 1-6 szénatomos alkil-, 2-6szénatomos alkenil-, 2-6 szénatomos alkinil-, 3-6 szénatomoscikioalkil-, cikloheteroalkil-, fenil- vagy heteroarilcsoport; amelyekadott esetben szubsztituáltak; R2, R3, R5, R6, R7, R8, R9, R10 és R11jelentése egymástól függetlenül hidrogénatom vagy adott esetbenszubsztituált 1-6 szénatomos alkilcsoport; R4 jelentése hidrogénatom,CNR26NR27R28 vagy 1-6 szénatomos alkil-, 2-6 szénatomos alkenil-, 2-6szénatomos alkinil-, 3-6 szénatomos cikloalkil-, cikloheteroalkil-,aril- vagy heteroarilcsoport, melyek, mindegyike adott esetbenszubsztituált; R12 jelentése adott esetben szubsztituált 1-6szénatomos alkil-, aril- vagy heteroarilcsoport; y és w jelentése 0, 1vagy 2; R13 jelentése hidrogénatom vagy 1-6 szénatomos alkil-, 2-6szénatomos alkenil-, 2-6 szénatomos alkinil-, 3-6 szénatomoscikloalkil-, cikloheteroalkil-, aril- vagy heteroarilcsoport, melyekmindegyike adott esetben szubsztituált; R14 és R15 jelentése egymástólfüggetlenül hidrogén- vagy halogénatom vagy 1-6 szénatomos alkil-,aril-, heteroaril- vagy 1-6 szénatomos alkoxicsoport, melyek adottesetben szubsztituáltak; R16 jelentése hidrogénatom, COR29 vagy 1-6szénatomos alkil-, 2-6 szénatomos alkenil-, 2-6 szénatomos alkinil-,aril- vagy heteroarilcsoport, melyek mindegyike adott esetbenszubsztituált; R17 és R29 jelentése egymástól függetlenül hidrogénatomvagy 1-6 szénatomos alkil-, 2-6 szénatomos alkenil-, 2-6 szénatomosalkinil-, 3-6 szénatomos cikloalkil-, cikloheteroalkil-, aril- vagyheteroarilcsoport, melyek mindegyike adott esetben szubsztituált; R18,R19, R20, R21, R22, R26, R27 és R28 jelentése egymástól függetlenülhidrogénatom vagy adott esetben szubsztituált 1-6 szénatomosalkilcsoport; R23 és R24 jelentése egymástól függetlenül hidrogénatomvagy 1-6 szénatomos alkil-, aril- vagy heteroarilcsoport, melyek adottesetben szubsztituáltak; és R25 jelentése adott esetben szubsztituált1-6 szénatomos alkil-, aril- vagy heteroarilcsoport; vagy ezeksztereoizomerjei vagy gyógyászatilag elfogadható sói. A találmánykiterjed az (I) általános képletű vegyületek alkalmazására 5-HT6-receptor által befolyásolt rendellenességek gyógykezelésére. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28564401P | 2001-04-20 | 2001-04-20 | |
| PCT/US2002/012512 WO2002085853A2 (en) | 2001-04-20 | 2002-04-19 | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0303801A2 true HUP0303801A2 (hu) | 2004-03-01 |
Family
ID=23095117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0303801A HUP0303801A2 (hu) | 2001-04-20 | 2002-04-19 | Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6831094B2 (hu) |
| EP (1) | EP1392682A2 (hu) |
| JP (1) | JP2004526781A (hu) |
| KR (1) | KR20030088507A (hu) |
| CN (1) | CN1293073C (hu) |
| AR (1) | AR034588A1 (hu) |
| AU (1) | AU2002309585B2 (hu) |
| BR (1) | BR0209047A (hu) |
| CA (1) | CA2444036A1 (hu) |
| EA (1) | EA200301143A1 (hu) |
| HU (1) | HUP0303801A2 (hu) |
| IL (1) | IL158448A0 (hu) |
| MX (1) | MXPA03009490A (hu) |
| NO (1) | NO20034647L (hu) |
| PL (1) | PL366639A1 (hu) |
| WO (1) | WO2002085853A2 (hu) |
| ZA (1) | ZA200309009B (hu) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1513809A1 (en) | 2002-06-05 | 2005-03-16 | F. Hoffmann-La Roche Ag | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders |
| RU2350602C2 (ru) * | 2002-12-03 | 2009-03-27 | Ф.Хоффманн-Ля Рош Аг | Аминоалкоксииндолы, как лиганды рецептора 5-нт6, для лечения заболеваний цнс |
| CN100422171C (zh) * | 2003-02-14 | 2008-10-01 | 惠氏公司 | 作为5-羟色胺-6配体的杂环-3-磺酰基吲唑 |
| SE0302760D0 (sv) * | 2003-10-20 | 2003-10-20 | Biovitrum Ab | New compounds |
| CN101291913A (zh) * | 2005-08-15 | 2008-10-22 | 惠氏公司 | 作为5-羟色胺-6配体的吖嗪基-3-磺酰基吲唑衍生物 |
| CN101282938A (zh) * | 2005-08-15 | 2008-10-08 | 惠氏公司 | 作为5-羟色胺-6配体的经取代3-磺酰基吲唑衍生物 |
| JP2009532471A (ja) * | 2006-04-05 | 2009-09-10 | ワイス | ５−ヒドロキシトリプタミン−６リガンドとしてのスルホニル−３−ヘテロシクリルインダゾール誘導体 |
| WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
| EP2029550A2 (en) * | 2006-06-01 | 2009-03-04 | Wyeth a Corporation of the State of Delaware | 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands |
| WO2009006267A2 (en) * | 2007-06-28 | 2009-01-08 | Wyeth | N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles |
| WO2011143430A1 (en) | 2010-05-12 | 2011-11-17 | Abbott Laboratories | Indazole inhibitors of kinase |
| ME02663B (me) | 2010-10-06 | 2017-06-20 | Glaxosmithkline Llc | Derivati benzimidazola kao inhibitori pi3 kinaze |
| CN104725295B (zh) | 2013-12-20 | 2019-05-24 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
| SG11201610407QA (en) | 2014-07-08 | 2017-01-27 | Sunshine Lake Pharma Co Ltd | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
| UA125318C2 (uk) | 2017-08-01 | 2022-02-16 | Тереванс Байофарма Ар Енд Ді Айпі, Елелсі | Піразоло- і триазолобіциклічні сполуки як інгібітори jak-кінази |
| CA3125039A1 (en) | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| WO2021108803A1 (en) | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as jak inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3835291A1 (de) | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
| US5274097A (en) * | 1988-04-19 | 1993-12-28 | Bayer Aktiengesellschaft | 1,3-disubstituted pyrrolidines |
| GB9103862D0 (en) * | 1991-02-25 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
| TW288010B (hu) * | 1992-03-05 | 1996-10-11 | Pfizer | |
| WO1995003298A1 (en) | 1993-07-19 | 1995-02-02 | Fujisawa Pharmaceutical Co., Ltd. | BENZIMIDAZOLE DERIVATIVES USEFUL AS DOPAMINE RECEPTOR ANTAGONIST, 5-HT RECEPTOR AGONIST OR α1 RECEPTOR ANTAGONIST |
| US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| JPH0940646A (ja) | 1995-07-27 | 1997-02-10 | Yamanouchi Pharmaceut Co Ltd | ベンゼン縮合環誘導体又はその塩 |
| GB9523462D0 (en) | 1995-11-16 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
| AU7526798A (en) * | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
| CA2378047A1 (en) | 1999-07-15 | 2001-01-25 | Methvin Isaac | Heterocyclic compounds for the treatment of migraine |
| CA2432654A1 (en) * | 2000-12-22 | 2002-07-04 | Wyeth | Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands |
| TW593278B (en) * | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| CN100422171C (zh) * | 2003-02-14 | 2008-10-01 | 惠氏公司 | 作为5-羟色胺-6配体的杂环-3-磺酰基吲唑 |
-
2002
- 2002-04-19 HU HU0303801A patent/HUP0303801A2/hu unknown
- 2002-04-19 US US10/126,805 patent/US6831094B2/en not_active Expired - Fee Related
- 2002-04-19 CN CNB028123409A patent/CN1293073C/zh not_active Expired - Fee Related
- 2002-04-19 PL PL02366639A patent/PL366639A1/xx unknown
- 2002-04-19 CA CA002444036A patent/CA2444036A1/en not_active Abandoned
- 2002-04-19 EA EA200301143A patent/EA200301143A1/ru unknown
- 2002-04-19 EP EP02736592A patent/EP1392682A2/en not_active Withdrawn
- 2002-04-19 JP JP2002583380A patent/JP2004526781A/ja active Pending
- 2002-04-19 MX MXPA03009490A patent/MXPA03009490A/es active IP Right Grant
- 2002-04-19 AU AU2002309585A patent/AU2002309585B2/en not_active Expired - Fee Related
- 2002-04-19 IL IL15844802A patent/IL158448A0/xx unknown
- 2002-04-19 WO PCT/US2002/012512 patent/WO2002085853A2/en active Application Filing
- 2002-04-19 AR ARP020101443A patent/AR034588A1/es not_active Application Discontinuation
- 2002-04-19 KR KR10-2003-7013584A patent/KR20030088507A/ko not_active Application Discontinuation
- 2002-04-19 BR BR0209047-3A patent/BR0209047A/pt not_active IP Right Cessation
-
2003
- 2003-10-17 NO NO20034647A patent/NO20034647L/no not_active Application Discontinuation
- 2003-11-19 ZA ZA200309009A patent/ZA200309009B/en unknown
-
2004
- 2004-09-24 US US10/949,061 patent/US20050065185A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002309585B2 (en) | 2008-01-31 |
| CN1518548A (zh) | 2004-08-04 |
| PL366639A1 (en) | 2005-02-07 |
| US20050065185A1 (en) | 2005-03-24 |
| WO2002085853A3 (en) | 2002-12-19 |
| CN1293073C (zh) | 2007-01-03 |
| EP1392682A2 (en) | 2004-03-03 |
| BR0209047A (pt) | 2004-08-10 |
| JP2004526781A (ja) | 2004-09-02 |
| IL158448A0 (en) | 2004-05-12 |
| ZA200309009B (en) | 2005-02-21 |
| EA200301143A1 (ru) | 2004-02-26 |
| CA2444036A1 (en) | 2002-10-31 |
| NO20034647L (no) | 2003-11-20 |
| MXPA03009490A (es) | 2004-02-12 |
| NO20034647D0 (no) | 2003-10-17 |
| WO2002085853A2 (en) | 2002-10-31 |
| US6831094B2 (en) | 2004-12-14 |
| US20030078286A1 (en) | 2003-04-24 |
| AR034588A1 (es) | 2004-03-03 |
| KR20030088507A (ko) | 2003-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0303801A2 (hu) | Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
| CA2487542A1 (en) | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | |
| MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
| RS28004A (en) | Azabicycle-substituted fused- heteroaryl compounds for the treatment of disease | |
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| HUP0204399A2 (en) | Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| HRP20070430T3 (en) | (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity | |
| WO2003080580A3 (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| SE0104332D0 (sv) | Therapeutic agents | |
| PE20030703A1 (es) | Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3 | |
| DE60311821D1 (de) | Dibenzylaminverbindung und deren medizinische verwendung | |
| TW200738682A (en) | Isoquinoline derivatives | |
| NO20075169L (no) | Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme. | |
| NO20090952L (no) | N-(aminoheteroaryl) - lh - indol-2-karboksamidderivater og fremstilling og terapeutisk anvendelse derav | |
| CA2445190A1 (en) | Indole, azaindole and related heterocyclic amidopiperazine derivatives | |
| MX2009006024A (es) | Derivados de heteroaril piridopirimidona sustituidos. | |
| JP2006507326A5 (hu) | ||
| HRP20040429B1 (en) | Sulphonamide derivatives, the preparation thereof and the application of same as medicaments | |
| NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| ATE476431T1 (de) | Piperidin- und azetidinderivate als glyt1- inhibitoren | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |